January 26, 2015 3:34 PM ET


Company Overview of Milestone Pharmaceuticals Inc.

Company Overview

Milestone Pharmaceuticals Inc., a drug development company, develops small molecule therapeutics for the treatment of inflammatory and cardiovascular diseases. Its product includes a short-acting calcium channel antagonist for the treatment of transient cardiovascular conditions, such as atrial arrhythmias and angina. The company was founded in 2003 and is based in Montreal, Canada.

6100 Royalmount Avenue

Montreal, QC H4P 2R2


Founded in 2003





Key Executives for Milestone Pharmaceuticals Inc.

Chief Executive Officer and Director
Chief Medical Officer
Chief Medical Advisor
Vice President of Chemistry & Manufacturing
Vice President of Drug Development
Compensation as of Fiscal Year 2014.

Milestone Pharmaceuticals Inc. Key Developments

Milestone Pharmaceuticals Receives FDA Clearance of MSP-2017 Phase 2 IND

Milestone Pharmaceuticals Inc. announced that it received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 study of MSP-2017 for the treatment of acute episodes of Paroxysmal Supraventricular Tachycardia (PSVT). The trial is expected to begin patient enrollment in early 2015. The trial design cleared by FDA is a multiple arm Phase 2, multi-center, placebo-controlled study of intranasal administration of MSP-2017 for the conversion of PSVT to sinus rhythm. The primary objective of this study will be to demonstrate the superiority of at least one dose of intranasal MSP-2017 over placebo in terminating PSVT induced in an electrophysiology laboratory. MSP-2017 is a novel and potent short-acting calcium channel antagonist for the treatment of PSVT, a potentially debilitating cardiac arrhythmia. MSP-2017 has successfully completed Phase 1 studies and is scheduled to start Phase 2 in First Quarter 2015. The product is being developed as a patient self-administered nasal spray to terminate PSVT episodes at-home. MSP-2017 has a rapid onset and reaches pharmacologically relevant plasma levels within 5 minutes of administration. MSP-2017 is designed to be short-acting, allowing it to be metabolized quickly after resolution of the PSVT episode. MSP-2017 will allow patients to terminate their PSVT episodes at home and avoid ER visits. MSP-2017 is intended to address a significant unmet medical need due to the lack of convenient, rapid, safe and effective self-administered products for the treatment of PSVT episodes in the home setting.

Milestone Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:30 AM

Milestone Pharmaceuticals Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-14-2015 10:30 AM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Milestone Pharmaceuticals, Inc. Announces Positive Phase 1 Data for MSP-2017 and Supports Advancement into Phase 2 in PSVT Patients

Milestone Pharmaceuticals Inc. announced data from a Phase 1 clinical trial conducted in Melbourne, Australia of MSP-2017, a novel calcium channel antagonist for the potential treatment of paroxysmal supraventricular tachycardia (PSVT). The results demonstrated that an intra-nasal formulation of MSP-2017 was well tolerated at single doses up to and including 140 mg with an excellent safety profile, desirable PK properties including rapid onset, and validating proof of concept by PR interval prolongation as measured by ECG. Milestone expects to initiate a Phase 2 clinical trial of MSP-2017 in patients with PSVT during the first half of 2015. The Phase 1 clinical trial included a randomized, double-blind, placebo-controlled, single ascending-dose study in 56 healthy volunteers. The primary objective of the study was to evaluate the safety, tolerability and pharmacokinetics of two intranasal formulations of MSP-2017 in a crossover design given as a single dose to seven successive cohorts of 8 healthy subjects each. All adverse events were mild in nature and no serious adverse events were reported. The Phase 1 study was undertaken following promising results in the preclinical evaluation of MSP-2017. In a series of in vivo experiments, MSP-2017 exhibited prolongation of the PR interval as measured by ECG. These results suggest MSP-2017 can impact AV nodal conduction, and support the potential of MSP-2017 to treat PSVT episodes.

Similar Private Companies By Industry

Company Name Region
enGene, Inc. Americas
Geneseeq Technology Inc. Americas
Quantum Genetix Canada Inc. Americas
Soricimed Biopharma Inc. Americas
Tyrogene Biotechnologies, Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Milestone Pharmaceuticals Inc., please visit www.milestonepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.